

## Special Issue

# Targeting Channel Proteins in Cancer

### Message from the Guest Editor

Ion channels are crucial proteins regulating all cell functions in physiology or pathological conditions. Their involvement in cancer promotion is progressively elucidated but it is necessary to deeply understand underlying mechanisms to use them as targets. Function or expression modification, localization or addressing, complex formation, microenvironment interaction, genetic regulation, or downstream signaling pathways are different processes related to ion channels altered in cancer cells and promote tumor development. In addition, other cells surrounding the tumor could show ion channel alteration promoting cancer evolution. Despite all the information already available, ion channels have not yet reached their full clinical value in the cancer field. This Special Issue will highlight all the new elements allowing the use of ion channels as therapeutic targets to fight against cancer development, covering both basic and more preclinical aspects.

---

### Guest Editor

Dr. Alban Girault

Laboratory of Cell and Molecular Physiology (LPCM), UR UPJV4667, Université de Picardie Jules Verne, Amiens, France

---

### Deadline for manuscript submissions

closed (15 January 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/139437](https://mdpi.com/si/139437)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)